Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Takes More Restructuring Steps

by Michael McCoy
July 29, 2013 | A version of this story appeared in Volume 91, Issue 30

The Swiss fine chemicals producer Lonza is continuing the restructuring process begun by new CEO Richard Ridinger. The company is ending a joint venture with Teva Pharmaceutical Industries to develop so-called biosimilar biologic drugs, saying the process will cost more than initially planned. Lonza is also closing its microbial biologics manufacturing plant in Hopkinton, Mass., and consolidating microbial operations in Visp, Switzerland. And the firm says it will consider selling the wood treatment chemicals business it acquired with its 2011 purchase of Arch Chemicals.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.